Bond Biosciences
Business Services · Missouri, United States · 1-10 Employees
View Company Info for Free
Overview
Headquarters
170 English Landing Dr Ste 201B, Parkvil...Website
bond.bioRevenue
<$5 MillionIndustry
ZI Rank: 1
Signal Type
Feb
Mar
Apr
May
Jun
Jul
ZI Rank
1
1
1
1
1
1
About Bond Biosciences
Bond Biosciences is a clinical-stage biotechnology company developing oral therapeutics for ion-related diseases. Its lead candidate, BBI-001, is designed to prevent excess iron absorption and treat hereditary hemochromatosis, with additional programs targeting other ion-related disorders.Explore more
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Bond Biosciences your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Click to see if Bond Biosciences had a recent Job posting/layoffs
Funding: Get notified immidiatlly once Bond Biosciences has new funding data
Earning: See what the market has to say on Bond Biosciences recently announced quarterly report
Product Launch: Get notified when Bond Biosciences launches new products
Check if Bond Biosciences has recently received funding, and reach out quickly before it becomes old news!
Congratulate Masked Content for being promoted to Masked Content at Bond Biosciences
Website visits: Recent activity has been detected on your website
Check out if Bond Biosciences is spiking on competitors!
Bond Biosciences, which may be a good buyer, showed buying intent in Masked Content Topic
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Recommended Actions
Reach out to Masked Content who joined Bond Biosciences as Masked Content
Find 3 more new buyers
Compare Similar Companies to Bond Biosciences
Compare insights from companies similar to Bond Biosciences, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Bond Biosciences
<$5M
1-10
Private
$10.3M
2015
N/A
Company Profile Activity
Activity Insights
Bond Biosciences is experiencing very low activity levels compared to other companies in the Business Services sector.
What does this means?
Bond Biosciences is drawing exceptional interest within the Business Services industry, suggesting notable developments or strong market momentum, learn more about Bond Biosciences.
Bond Biosciences financials insights
Gather financial insights about Bond Biosciences, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2021
Series A
$5M
2026
Stock/Share Issuance
$5.3M
Bond Biosciences Tech Stack
A closer look at the technologies used by Bond Biosciences
Most Recent Scoops
Project
Laboratory Operations, Medical Research, Clinical Operations
Funding
Funding
Event
Events
Funding
Bond Biosciences News & Media
Bond Biosciences, Inc. to Present at Biotech Showcase™ 2024
PARKVILLE, Mo.--(BUSINESS WIRE)-- #BBI001--Bond Biosciences, Inc., a privately held biopharmaceutical company focused on the discovery and development of first-in-class non-absorbed oral therapies that bind excess ions locally in the gastrointestinal (GI) tract to treat or prevent human disease announced today that it is presenting at Biotech Showcase™ 2024. The Biotech Showcase is taking place in San Francisco in parallel with the J.P. Morgan 42nd Annual Healthcare Conference. Dr. Cory BerklandBond Biosciences Announces First Dosing of Sentinel Patients in a Phase Ia/b Clinical Trial for a Novel Therapy to Treat Patients with Hemochromatosis
PARKVILLE, Mo.--(BUSINESS WIRE)--Phase Ia/b will assess the safety of BBI-001 and test the ability of BBI-001 to prevent iron uptake from food.Bond Biosciences Announces the Closing of a Series B Financing
NEW YORK--(BUSINESS WIRE)-- #BBI001--Bond’s clinical lead, BBI-001, is designed to rapidly and selectively bind dietary iron to reduce iron absorption in patients with iron overload.Bond Biosciences Announces Closing of Series A Financing | Business ...
NEW YORK--(BUSINESS WIRE)--Mar 30, 2021--
Read more news
Top Business Services Companies
Top companies in Canada by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Bond Biosciences
Sign Up For FreeTo access detailed company insights
Bond Biosciences is a clinical-stage biotechnology company developing oral therapeutics for ion-related diseases. Its lead candidate, BBI-001, is designed to prevent excess iron absorption and treat hereditary hemochromatosis, with additional programs targeting other ion-related disorders.... Read More
